EntreMed/Bristol to study thalidomide for brain cancer in "near future" -- IPO prospectus.
Executive Summary
ENTREMED/BRISTOL TO BEGIN STUDIES OF THALIDOMIDE FOR BRAIN CANCER in the "near future," according to EntreMed's initial public offering prospectus. The studies in brain cancer will be similar to ongoing Phase II trials of oral thalidomide therapy to inhibit the progression of breast and prostate cancer and Kaposi's sarcoma, which are being conducted in collaboration with Bristol-Myers Squibb and the National Cancer Institute, the prospectus indicates. The offering netted proceeds of over $43.4 mil. for EntreMed ("The Pink Sheet" June 17, p. 14).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth